Serum CYFRA 21-1 in Egyptian women with breast cancer

摘要: Introduction: Cytokeratin fragment 21.1 (CYFRA 21.1) assay detects a serum of cytokeratin 19 (CK19) and is employed in the diagnosis management lung cancer, particularly squamous cell histotype. Breast carcinoma has been demonstrated to express CK19 fragments primary metastatic lesions mRNA detectable peripheral blood from patients affected by breast cancer. Aim work: The aim present study was evaluate clinical significance CYFRA21-1 with cancer analyzing correlation between titers, clinicopathological factors prognosis comparison CA15.3 CEA tested same samples. Subjects methods: This included 60 25 healthy females as control group. Three samples were drawn each patient, before surgery, two weeks after surgery 6 cycles chemotherapy. One sample subject Serum separated kept frozen till used for estimation enzyme linked immunosorbent (ELISA) immunoradiometric (IRMA). Results: highly elevated than controls significantly associated tumor size, stage axillary lymph node involvement. superior diagnostic marker using ROC curve analysis. Higher levels poor patients. Conclusions: measurement CYFRA 21-1 may be useful detecting disease relapse assessing surgical chemotherapeutic efficacy. Further prospective studies greater number are required confirm our findings.